Tranexamic Acid : Nebulization vs IV Route for Hemoptysis

This study compares the effect of tranexamic acid on hemoptysis when given through the conventional IV route and Through nebulization.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemoptysis Hemorrhage Lung Diseases NEBULIZATION Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory Tranexamic Acid

Age range

12 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Services Hospital Lahore

Lahore, Punjab Province, 54000, Pakistan

About this study

The investigators are conducting a randomized controlled trial for the comparison of routes through which tranexamic acid can be given to control hemoptysis. The study participants will be divided into 2 groups randomly and 1 group will be assigned to use IV route while other will be assigned the nebulization route and the result variables include the time taken for complete control of hemoptysis and recurrence time. Another variable is the reduction in amout of blood in sputum after each intervention.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with mild to moderate hemoptysis < 600ml/ 24 hours of age 12 to 80 years and both genders.
Patients with hemoptysis due to infective pathology.
Patients with hemoptysis due to malignant pathology.

Exclusion criteria

Patients on antiplatelet therapy or aspirin
Hemoptysis after penetrating lung injury e.g. firearm injury
Patients with history of asthma

Treatment and study plan

Tranexamic acid (TXA)

Drug

In this study we are comparing the effect of tranexamic acid on hemoptysis when given through IV route and nebulization

Other names: nebulization

Primary outcomes

Time to control hemoptysis

Time frame: 48 hours

In this study the time taken by tranexamic acid to acehive comolete control of hemoptysis will be compared when given through IV and nebulization.

Sponsors and collaborators

Lead sponsor

University of Health Sciences Lahore

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Oct 8, 2025
Registry last updated: Nov 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed